Medical Devices · Salt Lake City, Utah, United States
$1.97
-3.43% (-$0.07)2026-07-10
Smart-Money SignalDistribution · 41/100— Insiders are net sellers over 90 days (-$76K, 8 sales vs 2 buys)
Revenue$14.0K
Net Income-$8.4M
EPS$-0.17
Price Performance
Historical data including institutional events
Company Profile
Z
Zhenya Lindgardt
CEO & Executive Director
Sera Prognostics, Inc., a womenâs health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States.
The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction.
The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
